Oct 21 (Reuters) - Inovio Pharmaceuticals Inc :
* INOVIO ANNOUNCES NEW DATA AT SCIENTIFIC CONFERENCES FOR LEAD CANDIDATE, INO-3107, AS A POTENTIAL TREATMENT FOR RRP
* INOVIO PHARMACEUTICALS INC - INO-3107 WELL TOLERATED, 81% OF PATIENTS REQUIRED FEWER SURGERIES POST-TREATMENT
* INOVIO PHARMACEUTICALS INC - 81% OF PATIENTS EXPERIENCED FEWER SURGICAL INTERVENTIONS POST-TREATMENT WITH INO-3107
* INOVIO PHARMACEUTICALS INC - INO-3107 WELL TOLERATED, MOST FREQUENT AES WERE INJECTION SITE PAIN AND FATIGUE
Source text for Eikon: Further company coverage:
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.